1-Aminomethyl-5-methoxyindane

1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity relative to DFMDA.^[1][2]

1-Aminomethyl-5-methoxyindane

Clinical data
Other names	AMMI
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (5-Methoxy-2,3-dihydro-1H-inden-1-yl)methanamine
CAS Number	1415750-28-5 N
PubChem CID	45091234
ChemSpider	24205063 Y
UNII	585V6BDH9X
CompTox Dashboard (EPA)	DTXSID801029881
Chemical and physical data
Formula	C11H15NO
Molar mass	177.247 g·mol−1
3D model (JSmol)	Interactive image
SMILES NCC1CCc2c1ccc(OC)c2
InChI InChI=1S/C11H15NO/c1-13-10-4-5-11-8(6-10)2-3-9(11)7-12/h4-6,9H,2-3,7,12H2,1H3 Y Key:WPBKCMLYKMDWRD-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

See also

• 2CB-Ind
• 1-Aminomethylindane
• para-Methoxyamphetamine (PMA)